Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2023-09-18 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science fait une mise au point sur le calendrier de l’EMA concernant l'examen de la demande d'autorisation de mise sur le marché du masitinib dans la SLA
Regulatory Filings Classification · 1% confidence The document is a press release dated September 18, 2023, from AB Science, providing an update on the European Medicines Agency (EMA) review timeline for their drug masitinib for ALS. It discusses an extension of the review clock due to new EMA directives regarding nitrosamine impurities and confirms the expected decision date (Q1 2024). This type of communication, which updates stakeholders on regulatory progress, clinical trial status, or key operational milestones outside of formal financial reporting (like 10-K or IR), is typically classified as an Investor Presentation (IP) if it's detailed, or often falls under Regulatory Filings (RNS) if it's a general, non-financial update. Given the focus on regulatory timelines and scientific updates rather than a formal financial report or a specific management change, it aligns best with a general regulatory/investor update. Since it is not a formal financial report (10-K, IR, ER) and is not a presentation deck (IP), it fits the broad category of Regulatory Filings (RNS) as a general corporate announcement regarding regulatory progress. However, because it is a detailed update specifically aimed at investors regarding a key product approval timeline, 'Investor Presentation' (IP) might also be considered if the content were more strategic. Given the structure (press release format detailing regulatory steps), RNS is the most appropriate fallback for non-standard, non-financial regulatory updates. Upon review, this is a standard press release providing an update on regulatory status, which often falls under RNS or sometimes IP if it were a deck. Given the options, RNS (Regulatory Filings) is the best fit for a general regulatory status update press release.
2023-09-18 French
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science dated September 18, 2023, providing an update on the European Medicines Agency's (EMA) timetable for examining the marketing authorization application for masitinib in ALS. It discusses regulatory processes, stop-clock extensions, and expected decision timelines (Q1 2024). This type of communication, detailing progress or setbacks in regulatory submissions, clinical trials, or specific legal/regulatory interactions, fits best under the category of general regulatory updates or investor relations material that isn't a full financial report (10-K, IR) or a standard earnings release (ER). Since it is a specific update on a regulatory process (EMA review), and not a general announcement of a report being published (RPA) or a standard miscellaneous filing (RNS), it most closely aligns with providing specific information relevant to investors regarding the company's pipeline progress. However, none of the provided codes perfectly capture 'Regulatory Pipeline Update'. Given the options, it is an announcement concerning the company's operations and regulatory status. It is not a legal proceeding (LTR), nor a management change (MANG). It is an update on a drug application review. In the context of the provided definitions, this is a specific, non-financial, operational update. If it were a legal proceeding, it would be LTR. Since it is a regulatory update concerning a drug application, and not a general regulatory filing fallback (RNS), the closest fit among the specific operational/investor categories is difficult. Given the nature of the content—a specific update on a regulatory review process—it is often classified as a general Regulatory Filing (RNS) if a more specific category like 'Clinical Trial Update' or 'Regulatory Submission Status' is missing. However, since it is a formal press release providing key operational news, and not a generic regulatory filing, I will check if it fits 'LTR' (Legal Proceedings Report) - no, it's regulatory approval process. It is not a financial report. It is an announcement of an event/status update. Given the options, 'RNS' (Regulatory Filings - general/fallback) is the most appropriate general category for specific, non-financial, non-management, non-legal updates that don't fit elsewhere, or it could be argued as an Investor Presentation (IP) if it were a slide deck, which it is not. I will classify this as RNS as it is a specific regulatory status update that doesn't fit the other defined categories like LTR, ER, or 10-K.
2023-09-18 English
AB Science - Résultats de l'Assemblée Générale Mixte du 30 juin 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled "RESULTATS DE L'ASSEMBLEE GENERALE MIXTE DU 30 JUIN 2023" (Results of the Combined General Meeting of June 30, 2023). It details the voting outcomes for numerous resolutions, categorized as 'Résolutions ordinaires' and 'Résolutions extraordinaires'. This content directly corresponds to the reporting of official results from a shareholder meeting. The most appropriate classification is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the focus is on the *results* of the vote, not the presentation materials (AGM-R) or the proxy solicitation (PSI).
2023-07-03 French
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
Regulatory Filings Classification · 1% confidence The document is a press release dated June 26, 2023, announcing that AB Science received a Notice of Allowance from the European Patent Office for a patent covering masitinib in the treatment of mCRPC. The content focuses on intellectual property protection, clinical trial results (AB12003), and company background. This type of announcement, detailing specific legal/IP developments and clinical data summaries outside of standard periodic financial reports (10-K, IR, ER), most closely aligns with a general regulatory announcement or a specific update related to intellectual property or legal matters. Since there is no specific code for 'Patent Grant/Allowance Announcement', and it is not a formal financial report, a legal proceeding report (LTR), or a management discussion (MDA), the most appropriate general category for a significant, non-financial regulatory/corporate update is 'Regulatory Filings' (RNS). It is not a proxy statement (PSI), earnings release (ER), or management change (MANG). Given the focus on patent protection, it is a specific corporate event announcement.
2023-06-26 English
AB Science reçoit un avis d’acceptation pour un brevet européen pour le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant (mCRPC)
Regulatory Filings Classification · 1% confidence The document is a press release dated June 26, 2023, announcing that the European Patent Office has issued a notice of acceptance for a patent concerning Masitinib for treating metastatic castration-resistant prostate cancer (mCRPC). The text details the patent protection extension, clinical study results (AB12003), and company background. This type of announcement, focusing on intellectual property (patent grant/acceptance) and clinical/scientific updates, is characteristic of a general regulatory filing or a specific announcement related to corporate development, but it is not a formal financial report (like 10-K, IR, ER, or MRQ). Since it is a specific announcement about a legal/IP development (patent acceptance) that doesn't fit perfectly into the other specific categories (like DIV, CAP, MANG, etc.), the most appropriate classification is the general regulatory announcement fallback category, RNS, as it is a formal communication to the market about a significant corporate event. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K) as it lacks comprehensive financial statements or period-end results. It is not a Director's Dealing (DIRS) or Management Change (MANG). It is an announcement of an IP event, which falls under the broad 'Regulatory Filings' (RNS) category when a more specific IP filing code is unavailable.
2023-06-26 French
AB Science annonce la délivrance d’un brevet canadien pour le masitinib dans le traitement de la SLA avec une protection jusqu’en 2037
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science dated June 1, 2023, announcing that the Canadian patent office has issued an acceptance notice for a patent related to Masitinib for the treatment of ALS. The text details the patent number, its expiration date (2037), and how it complements existing intellectual property protection in other major geographies (Europe, US, China, etc.). This type of announcement, focusing on intellectual property rights, patents, and regulatory milestones (like the NOC/c status with Health Canada), is characteristic of communications aimed at investors regarding the company's core assets and future commercial viability. It is not a full financial report (10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a specific update concerning intellectual property protection, which falls under the broader category of Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the focus on patent issuance and IP strategy, 'IP' (Investor Presentation) is a strong candidate, as these announcements often serve as key updates for investors regarding asset value. However, since the core subject is the granting of a patent, which is a specific legal/regulatory event, and it doesn't contain a detailed strategic presentation, 'RNS' (Regulatory Filings - the fallback for specific announcements not covered elsewhere) is also plausible. Comparing the definitions, 'IP' usually implies a presentation deck, while this is a news release about a specific legal/IP event. Since there is no specific code for 'Patent Grant Announcement', and it is a formal announcement of a legal/regulatory milestone, 'RNS' is the most appropriate general regulatory filing category, although 'IP' is related to investor focus. Given the high specificity of the other codes, and this being a formal announcement of a legal/IP development, RNS is the safest classification for a non-financial, non-management specific regulatory update.
2023-06-01 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.